Search

Your search keyword '"Verhoeven, Maxime M.A."' showing total 13 results
Start Over Author "Verhoeven, Maxime M.A."
13 results on '"Verhoeven, Maxime M.A."'

3. A sex difference in handscan scores in rheumatoid arthritis patients and controls? An ongoing analysis of the sex difference and other potential confounders

Author

Lab Reumatologie/Klinische Immunologie, Infection & Immunity, MS Reumatologie/Immunologie/Infectie, Verhoeven, Maxime M.A., Westgeest, Antonius A.A., Jacobs, Johannes W.G., Lab Reumatologie/Klinische Immunologie, Infection & Immunity, MS Reumatologie/Immunologie/Infectie, Verhoeven, Maxime M.A., Westgeest, Antonius A.A., and Jacobs, Johannes W.G.

Published
2021

4. Unravelling the Cost of Biological Strategies in Rheumatoid Arthritis: A Kaleidoscope of Methodologies, Interpretations, and Interests

Author

MS Reumatologie/Immunologie/Infectie, Lab Reumatologie/Klinische Immunologie, Infection & Immunity, Regenerative Medicine and Stem Cells, JC onderzoeksprogramma Methodologie, Jacobs, Johannes W.G., Verhoeven, Maxime M.A., Welsing, Paco M.J., MS Reumatologie/Immunologie/Infectie, Lab Reumatologie/Klinische Immunologie, Infection & Immunity, Regenerative Medicine and Stem Cells, JC onderzoeksprogramma Methodologie, Jacobs, Johannes W.G., Verhoeven, Maxime M.A., and Welsing, Paco M.J.

Published
2021

5. Effect on costs and quality-adjusted life-years of treat-to-target treatment strategies initiating methotrexate, or tocilizumab, or their combination in early rheumatoid arthritis

Author

Infection & Immunity, Lab Reumatologie/Klinische Immunologie, MS Reumatologie/Immunologie/Infectie, Regenerative Medicine and Stem Cells, JC onderzoeksprogramma Methodologie, Verhoeven, Maxime M.A., Tekstra, Janneke, van Laar, Jacob M., Pethö-Schramm, Attila, Borm, Michelle E.A., Bijlsma, Johannes W.J., Jacobs, Johannes W.G., Lafeber, Floris P.J.G., Welsing, Paco M.J., Infection & Immunity, Lab Reumatologie/Klinische Immunologie, MS Reumatologie/Immunologie/Infectie, Regenerative Medicine and Stem Cells, JC onderzoeksprogramma Methodologie, Verhoeven, Maxime M.A., Tekstra, Janneke, van Laar, Jacob M., Pethö-Schramm, Attila, Borm, Michelle E.A., Bijlsma, Johannes W.J., Jacobs, Johannes W.G., Lafeber, Floris P.J.G., and Welsing, Paco M.J.

Published
2021

7. Effect on Costs and Quality-adjusted Life-years of Treat-to-target Treatment Strategies Initiating Methotrexate, or Tocilizumab, or Their Combination in Early Rheumatoid Arthritis

Author

Verhoeven, Maxime M.A., primary, Tekstra, Janneke, additional, van Laar, Jacob M., additional, Pethö-Schramm, Attila, additional, Borm, Michelle E.A., additional, Bijlsma, Johannes W.J., additional, Jacobs, Johannes W.G., additional, Lafeber, Floris P.J.G., additional, and Welsing, Paco M.J., additional

Published
2020
Full Text
View/download PDF

8. Validation of a Prognostic Multivariable Prediction Model for Insufficient Clinical Response to Methotrexate in Early Rheumatoid Arthritis and Its Clinical Application in Evidencio

Author

Research UMC Utrecht, Infection & Immunity, Lab Reumatologie/Klinische Immunologie, PMC Research, MS Reumatologie/Immunologie/Infectie, Unit Opleiding Aios, Regenerative Medicine and Stem Cells, Gosselt, Helen R., Verhoeven, Maxime M.A., de Rotte, Maurits C.F.J., Pluijm, Saskia M.F., Muller, Ittai B., Jansen, Gerrit, Tekstra, Janneke, Bulatović-Ćalasan, Maja, Heil, Sandra G., Lafeber, Floris P.J.G., Hazes, Johanna M.W., de Jonge, Robert, Research UMC Utrecht, Infection & Immunity, Lab Reumatologie/Klinische Immunologie, PMC Research, MS Reumatologie/Immunologie/Infectie, Unit Opleiding Aios, Regenerative Medicine and Stem Cells, Gosselt, Helen R., Verhoeven, Maxime M.A., de Rotte, Maurits C.F.J., Pluijm, Saskia M.F., Muller, Ittai B., Jansen, Gerrit, Tekstra, Janneke, Bulatović-Ćalasan, Maja, Heil, Sandra G., Lafeber, Floris P.J.G., Hazes, Johanna M.W., and de Jonge, Robert

Published
2020

9. Effectiveness and safety over 3 years after the 2-year U-Act-Early trial of the strategies initiating tocilizumab and/or methotrexate

Author

Lab Reumatologie/Klinische Immunologie, Infection & Immunity, MS Reumatologie/Immunologie/Infectie, Regenerative Medicine and Stem Cells, JC onderzoeksprogramma Methodologie, Verhoeven, Maxime M.A., Tekstra, Janneke, Welsing, Paco M.J., Pethö-Schramm, Attila, Borm, Michelle E.A., Bruyn, George A.W., Bos, Reinhard, Griep, Ed N., Klaasen, Ruth, van Laar, Jacob M., Lafeber, Floris P.J.G., Bijlsma, Johannes W.J., de Hair, Marjolein J.H., Jacobs, Johannes W.G., Lab Reumatologie/Klinische Immunologie, Infection & Immunity, MS Reumatologie/Immunologie/Infectie, Regenerative Medicine and Stem Cells, JC onderzoeksprogramma Methodologie, Verhoeven, Maxime M.A., Tekstra, Janneke, Welsing, Paco M.J., Pethö-Schramm, Attila, Borm, Michelle E.A., Bruyn, George A.W., Bos, Reinhard, Griep, Ed N., Klaasen, Ruth, van Laar, Jacob M., Lafeber, Floris P.J.G., Bijlsma, Johannes W.J., de Hair, Marjolein J.H., and Jacobs, Johannes W.G.

Published
2020

10. Vitamin B12 Intake From Animal Foods, Biomarkers, and Health Aspects

Author

Obeid, Rima, Heil, Sandra G., Verhoeven, Maxime M.A., Heuvel, Ellen G.H.M., van den, Groot, Lisette C.P.G.M., De, Eussen, Simone J.P.M., Obeid, Rima, Heil, Sandra G., Verhoeven, Maxime M.A., Heuvel, Ellen G.H.M., van den, Groot, Lisette C.P.G.M., De, and Eussen, Simone J.P.M.

Abstract

The EAT-Lancet commission recently suggested that transformation to healthy diets by 2050 will require a reduction of at least 50% in consumption of foods such as red meat and sugar, and a doubling in the global consumption of fruits, vegetables, nuts, and legumes. A diet rich in plant-based foods and with fewer animal source foods confers both improved health and environmental benefits. Notably, the risk of vitamin B12 deficiency increases when consuming a diet low in animal products. Humans are dependent on animal foods such as dairy products, meat, fish and eggs. Vitamin B12 deficiency is common worldwide, especially in populations with low consumption of animal foods because of low socioeconomic status, ethical reasons, or because of their lifestyle (i.e., vegans). According to the European Food Safety Authoroty, the recommended adequate intake of vitamin B12 is 4.0 μg/d for adults, and vitamin B12 requirements are higher during pregnancy and lactation. Infants and children from deficient mothers and elderly people are at risk for vitamin B12 deficiency. Diagnosis of vitamin B12 deficiency is hampered by low specificity of available biomarkers, and there is no consensus yet regarding the optimal definition of low vitamin B12 status. In general, a combination of at least two biomarkers is recommended. Therefore, this review presents an overview of vitamin B12 biochemistry and its biomarkers. We further summarize current recommendations of vitamin B12 intake, and evidence on the associations of vitamin B12 intake from different nutrient-dense animal foods with vitamin B12 status markers. Finally, potential consequences of low vitamin B12 status on different health outcomes for pregnant women, infants and elderly are presented.

Published
2019

11. Initiating tocilizumab, with or without methotrexate, compared with starting methotrexate with prednisone within step-up treatment strategies in early rheumatoid arthritis : an indirect comparison of effectiveness and safety of the U-Act-Early and CAMERA-II treat-to-target trials

Author

Verhoeven, Maxime M.A., De Hair, Marjolein J.H., Tekstra, Janneke, Bijlsma, Johannes W.J., Van Laar, Jacob M., Pethoe-Schramm, Attila, Borm, Michelle E.A., Ter Borg, Evert Jan, Linn-Rasker, Suzanne P., Teitsma, Xavier M., Lafeber, Floris P.J.G., Jacobs, Johannes W.G., Welsing, Paco M.J., Verhoeven, Maxime M.A., De Hair, Marjolein J.H., Tekstra, Janneke, Bijlsma, Johannes W.J., Van Laar, Jacob M., Pethoe-Schramm, Attila, Borm, Michelle E.A., Ter Borg, Evert Jan, Linn-Rasker, Suzanne P., Teitsma, Xavier M., Lafeber, Floris P.J.G., Jacobs, Johannes W.G., and Welsing, Paco M.J.

Published
2019

12. Initiating tocilizumab, with or without methotrexate, compared with starting methotrexate with prednisone within step-up treatment strategies in early rheumatoid arthritis: an indirect comparison of effectiveness and safety of the U-Act-Early and CAMERA-II treat-to-target trials

Author

UMC Utrecht, Lab Reumatologie/Klinische Immunologie, MS Reumatologie/Immunologie/Infectie, Infection & Immunity, Regenerative Medicine and Stem Cells, JC onderzoeksprogramma Methodologie, Verhoeven, Maxime M.A., De Hair, Marjolein J.H., Tekstra, Janneke, Bijlsma, Johannes W.J., Van Laar, Jacob M., Pethoe-Schramm, Attila, Borm, Michelle E.A., Ter Borg, Evert Jan, Linn-Rasker, Suzanne P., Teitsma, Xavier M., Lafeber, Floris P.J.G., Jacobs, Johannes W.G., Welsing, Paco M.J., UMC Utrecht, Lab Reumatologie/Klinische Immunologie, MS Reumatologie/Immunologie/Infectie, Infection & Immunity, Regenerative Medicine and Stem Cells, JC onderzoeksprogramma Methodologie, Verhoeven, Maxime M.A., De Hair, Marjolein J.H., Tekstra, Janneke, Bijlsma, Johannes W.J., Van Laar, Jacob M., Pethoe-Schramm, Attila, Borm, Michelle E.A., Ter Borg, Evert Jan, Linn-Rasker, Suzanne P., Teitsma, Xavier M., Lafeber, Floris P.J.G., Jacobs, Johannes W.G., and Welsing, Paco M.J.

Published
2019

13. Effect on Costs and Quality-adjusted Life-years of Treat-to-target Treatment Strategies Initiating Methotrexate, or Tocilizumab, or Their Combination in Early Rheumatoid Arthritis

Author

Verhoeven, Maxime M.A., Tekstra, Janneke, van Laar, Jacob M., Petho¨-Schramm, Attila, Borm, Michelle E.A., Bijlsma, Johannes W.J., Jacobs, Johannes W.G., Lafeber, Floris P.J.G., and Welsing, Paco M.J.

Abstract

ObjectiveOur study aimed to evaluate the cost effectiveness of initiating tocilizumab (TCZ) ± methotrexate (MTX) versus initiating MTX as treat-to-target treatment strategies over 5 years in early disease-modifying antirheumatic drug (DMARD)-nai¨ve rheumatoid arthritis (RA).MethodsData on resource use were collected with questionnaires at baseline, 3, 6, 12, and 24 months, and yearly thereafter, and were converted to costs using Dutch reference prices. Quality-adjusted life-years (QALY) were calculated using the EQ5D5L, with utility based on Dutch tariff or estimated by the Health Assessment Questionnaire. To account for missing cost data and QALY data and for sample uncertainty, first bootstraps (10,000 samples) were obtained. Second, single imputation using chained equations nested within these bootstrap samples was performed. An economic evaluation was performed for TCZ + MTX and TCZ, compared to MTX, as initial treatment in a treat-to-target strategy from a healthcare and societal perspective over 5 years. Several sensitivity analyses were performed.ResultsMean differences in QALY were small and not significant (TCZ + MTX vs MTX: 0.06, 95% CI –0.02 to 0.13; TCZ vs. MTX: –0.03, 95% CI –0.05 to 0.11). Limited savings in indirect nonhealthcare costs and productivity loss costs (for TCZ only) were observed, but these did not compensate for the higher medication costs. Sensitivity analyses did not materially change these findings, although lower-priced TCZ, or reserving TCZ as initial therapy for prognostically unfavorable RA patients, improved cost effectiveness considerably but did not individually lead to a strategy being cost effective.ConclusionBased on our analyses, early initiation of TCZ + MTX is not cost effective compared to MTX initiation in a step-up treat-to-target treatment strategy over 5 years in early RA patients.

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results